Trump administration initiates Section 232 investigation on medical supplies
Podcast
07: IP policy through an “America first” lens
Charting the course for US innovation
Alert
Life Science & Healthcare Private Capital Risk: Q2 2025 Update
Alert
DOJ and HHS Relaunch False Claims Act Working Group, Sharpen Healthcare Enforcement Priorities
Alert
Arkansas Bans PBMs from Owning Pharmacies, Escalating Scrutiny of Vertical Integration in Pharmacy Distribution
Alert
Life Science Private Equity Risk
Alert
Trump Administration Initiates Section 232 Investigations on Pharmaceuticals and Semiconductors
Alert
China Released First-of-Its-Kind Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks
Alert
First International Procurement Instrument case relating to EU medical devices in China’s public procurement market. The key question is what comes next?
Article
United States: Pharmaceutical Antitrust 2025
Alert
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024
Event
ABA 2024 Antitrust Spring Meeting
Alert
DOJ Antitrust Division Announces Deferred Prosecution Agreements with Two Pharmaceutical Companies Containing “Extraordinary” Divestiture Remedy
Article
United States: Pharmaceutical Antitrust 2024
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Insight
Tech continues to dominate
Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out
Insight
PMB performs as pharma groups repurpose their portfolios
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences
Article
United States: Pharmaceutical Antitrust 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Alert
Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate
Alert
Drug Pricing Issues to Watch in 2022
Article
Lexology GTDT: EU Antitrust Developments in the Pharmaceutical Sector
Article
United States: Pharmaceutical Antitrust 2022
Alert
HHS Report Reiterates Biden Administration Support for Wide-Ranging Action to Address Drug Prices
Alert
States Remain the Drivers of New Drug Pricing Legislation As Washington Weighs In
Alert
House Republicans Introduce Bill to Renew 2015 Trade Promotion Authority Law and Establish New Negotiating Objectives for Pharmaceuticals
Alert
What Does President Biden’s July 9, 2021 Executive Order on Competition Mean for the Pharma Industry?
Insight
Global PE posts record buyout value in Q2 thanks to TMT, pharma
Increasing cooperation between global PE players is pushing up price tags
Insight
What’s next for drug pricing in the US?
New challenges may lie ahead for the pharmaceutical industry
Alert
Federal Lawmakers Turn Their Sights to Drug Pricing, Introducing a Package of Bills Seeking Changes to Antitrust and Patent Law
Insight
US antitrust spotlight on the pharmaceutical industry
Companies seeking mergers can expect scrutiny and litigation
Alert
President Biden Signs Legislation Boosting Generic and Biosimilar Drugs
Alert
Elimination of Medicaid Rebate Cap in the Latest COVID-19 Relief Package—The First Legislative Action on Drug Pricing Under the Biden Administration
